Canada markets close in 34 minutes

Basilea Pharmaceutica AG (BPMUF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
47.000.00 (0.00%)
As of 1:24PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close47.00
Open47.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range47.00 - 47.00
52 Week Range45.05 - 61.00
Volume100
Avg. Volume1
Market Cap557.838M
Beta (5Y Monthly)0.95
PE Ratio (TTM)N/A
EPS (TTM)-4.67
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Basilea presents preclinical data on synergy between derazantinib and paclitaxel in gastric tumor models at ANE Conference

    Basel, Switzerland, October 11, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the presentation of data from preclinical studies demonstrating synergistic anti-tumor effects in a number of gastric cancer models for the combination of Basilea’s fibroblast growth factor receptor (FGFR) inhibitor, derazantinib, with the chemotherapy paclitaxel. The data were presented at the AACR-NCI-EORTC (ANE) Virtual International Conference on Molecular Targets and Cancer Therapeutics, that took pl

  • GlobeNewswire

    Basilea’s partner Asahi Kasei Pharma filed New Drug Application for the marketing authorization of isavuconazole in Japan

    Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland, September 30, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that its partner Asahi Kasei Pharma Corporation (Asahi Kasei Pharma) has filed a New Drug Application (NDA) for the marketing authorization of isavuconazole (Cresemba®) in Japan for the treatment of the fungal infections aspergillosis, mucormycosis and cryptococcosis. The filing triggers a CHF 5 million milestone payment from Asahi Kasei Pharma to Basilea. David

  • GlobeNewswire

    Basilea presents full safety and efficacy data set on derazantinib in patients with FGFR2 fusion-positive iCCA at ESMO congress

    – Progression-free survival (PFS) of derazantinib monotherapy increased to eight months Basel, Switzerland, September 17, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the reporting of the updated efficacy and safety results from cohort 1 of the phase 2 study FIDES-01, which evaluated its fibroblast growth factor receptor (FGFR) inhibitor, derazantinib, in patients with FGFR2 fusion-positive advanced or metastatic intrahepatic cholangiocarcinoma (iCCA), a type of bile duct cancer,